Twilight Litaka Pharma Peer Comparison

NSE: TWILITAKA | BSE: 506985

₹2.88

₹-0.15 (-4.95%)

As on 01-Jan-2015IST

Market cap

₹7 Cr

Revenue (TTM)

₹13 Cr

P/E Ratio

P/B Ratio

-0

Div. Yield

0 %

Edit

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	7	30,160	25,975	26,309	23,777
Revenue (₹ Cr)	13	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	-147.22	414.00	-371.81	387.35	288.22
Net Margin (%)	-1,169.22	11.23	-3.93	26.01	14.79
RoE (%)	--	8.38	-3.85	25.18	29.77
Price to Earnings	--	73.74	--	68.12	82.50
Price-To-Book	-0.05	5.99	3.24	15.25	17.71

Income Statement (₹ Cr)

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	31.50	4,830.36	--	76.11	41.58
Total Income	31.51	4,914.64	--	76.68	41.73
Total Expenditure	40.46	3,850.53	--	69.99	30.00
EBITDA	-8.95	979.83	--	6.12	11.59
Depreciation	5.39	139.92	--	0.80	3.35
EBIT	-14.34	839.91	--	5.32	8.24
Interest	0.41	83.35	--	1.58	2.34
Other Income	0.00	84.28	--	0.56	0.14
Exceptional Items	-125.45	49.83	--	--	--
Profit before Tax	-140.20	890.67	--	4.31	6.04
Provision for Tax	1.17	47.88	--	1.44	1.54
Profit after Tax	-140.20	842.79	--	2.86	4.50

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	-132.30	3,581.47	--	10.77	44.83
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	39.25	1,161.18	--	1.29	10.36
Current Liabilities	424.39	1,743.20	--	26.33	21.34
Total Liabilities	331.35	6,622.02	--	38.71	76.53

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	112.86	3,266.10	--	7.38	51.75
Current Assets	218.48	3,355.92	--	31.01	24.78
Total Assets	331.35	6,622.02	--	38.71	76.53
Total Debt*	321.98	1,906.08	--	12.17	21.09
Net Current Assets	-205.91	1,612.72	--	4.68	3.44
Contingent Liabilities	107.19	267.40	--	--	4.70

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	1.52	1,476.29	--	-0.21	6.29
Cash Flow from Investing Activities	-0.36	-851.62	--	-2.00	-5.46
Cash from Financing Activities	-0.66	-601.32	--	2.17	-0.58
Net Cash Inflow / Outflow	0.50	23.35	--	-0.04	0.25

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	-55.00	18.98	--	29.97	13.38
ROE (%)	0.00	30.04	--	30.26	19.08
ROA (%)	-35.44	13.36	--	8.85	6.16
EBIT Margin (%)	-28.41	22.03	--	8.78	28.21
Net Margin (%)	-444.96	17.15	--	3.74	10.78
Cash Profit Margin (%)	-427.90	20.32	--	4.81	18.86

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	-90.69	-13.89	--	37.10	12.11
EBIT Growth (%)	80.33	-49.66	--	30.95	21.82
Net Profit Growth (%)	17.99	-46.64	--	39.55	58.36
EPS Growth (%)	17.99	-56.04	--	39.55	58.36
Book Value Growth (%)	-6,435.70	36.37	--	32.03	21.09

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	0.00	6.59	--	0.00	0.00
Price / Book Value	-0.11	1.55	--	0.00	0.00
Dividend Yield (%)	0.00	2.19	--	--	--
EV/EBITDA	-37.56	5.73	--	2.02	3.52
Market Cap (₹ Cr)	15.09	5,016.58	--	0.00	0.00

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	-2.33	0.54	--	1.13	0.47
Short term debt to equity ratio	-1.84	0.06	--	0.84	0.23
Current Ratio	0.51	1.93	--	1.18	1.16
Quick Ratio	0.51	1.36	--	0.75	1.11
Interest Coverage	-341.46	11.69	--	3.73	3.58

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	663.25	9.96	--	17.81	33.85
Asset Turnover	0.08	0.77	--	2.35	0.57
Receivable days	2,740.44	54.33	--	58.46	106.93
Inventory Days	342.60	77.43	--	41.85	10.49
Payable days	569.97	120.43	--	91.25	213.33
Cash Conversion Cycle	2,513.07	11.32	--	9.06	-95.91

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.